A Prospective, Multicentre, Open Label, Non-controlled, Observational, 24-week Study in Patients Using NovoMix® 30 (Biphasic Insulin Aspart 30) for Treatment of Type 1 and Type 2 Diabetes Mellitus in Romania.
Phase of Trial: Phase IV
Latest Information Update: 21 Feb 2016
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 31 Aug 2018 Biomarkers information updated
- 24 May 2012 Official title amended as reported by ClinicalTrials.gov.
- 16 Oct 2009 Actual patient number (942) added as reported by ClinicalTrials.gov.